DEXAMETHASONE SODIUM PHOSPHATE
Generic: DEXAMETHASONE SODIUM PHOSPHATE
Eugia US LLCManufacturer
INTRAMUSCULAR, INTRAVENOUSRoute
DEXAMETHASONE SODIUM PHOSPHATEActive Substance
2020-06-05Original Approval
DEXAMETHASONE SODIUM PHOSPHATE is FDA application ANDA210966, sponsored by EUGIA PHARMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class III2017-11-06
Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), packaged in 25 x 1 mL Vials per sFailed Impurities/Degradation Specifications: high out of specification results for Dexamethasone ad
Class II2024-05-23
Dexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only, Distributed byFailed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phospha
Class III2017-11-06
Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mFailed Impurities/Degradation Specifications: high out of specification results for Dexamethasone ad
Class II2026-02-04
Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple Dose Vials, Rx only, ManufacFailed Impurities/Degradation Specifications - OOS impurities result observed during long term stabi
Top Reported Reactions
1
OFF LABEL USE
967 reports
2
NAUSEA
620 reports
3
PYREXIA
620 reports
4
ANAEMIA
508 reports
5
DRUG INEFFECTIVE
490 reports
6
DIARRHOEA
479 reports
7
MYELOSUPPRESSION
460 reports
8
WHITE BLOOD CELL COUNT DECREASED
460 reports
9
NEUTROPHIL COUNT DECREASED
458 reports
10
PLATELET COUNT DECREASED
457 reports